A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,101–1,200 of 3,965
Tzilas, V., Τzouvelekis, Α., Bouros, E., Karampitsakos, Τ., Ntassiou, M., Avdoula, E., Trachalaki, A., Antoniou, K. M., Raghu, G., & Bouros, D. E. (2020) · ERJ Open Research · doi:10.1183/23120541.00152-2020 · Cited by 36
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Sugino, K., Ono, H., Watanabe, N., Shimizu, S., Ando, M., Tsuboi, E., Homma, S. A., & Kishi, K. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01595-3 · Cited by 35
Hino, T., Lee, K. S., Han, J., Hata, A., Ishigami, K., & Hatabu, H. (2021) · Korean Journal of Radiology · doi:10.3348/kjr.2020.1132 · Cited by 34
The Role of miRNAs in Extracellular Matrix Repair and Chronic Fibrotic Lung Diseases
Usman, K., Hsieh, A., & Hackett, T. (2021) · Cells · doi:10.3390/cells10071706 · Cited by 38
Moran‐Mendoza, O., Ritchie, T., & Aldhaheri, S. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000815 · Cited by 38
Wan, H., Huang, X., Cong, P., He, M., Chen, A., Wu, T., Dai, D., Li, W., Gao, X., Tian, L., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.711239 · Cited by 33
“Idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease of unknown etiology (King et al., 2014; Martinez et al., 2017; Raghu et al., 2018), is characterized by diffuse alveolar inflammation and alveolar structural damage (Xu et al.”
BackgroundBeghé, B., Cerri, S., Fabbri, L. M., & Marchioni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179292 · Cited by 35
Cough in Idiopathic Pulmonary Fibrosis
Mann, J., Goh, N. S. L., Holland, A. E., & Khor, Y. H. (2021) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2021.751798 · Cited by 40
“¶Note in the ASCEND (48) and CAPACITY (49) studies 111 of 624 patients with IPF were on an Angiotensin-converting enzyme (ACE) inhibitor at randomization (50). sampled with bronchoalveolar lavage (30).”
MethodCleemput, J. V., Sonaglioni, A., Wuyts, W. A., Bengus, M., Stauffer, J. L., & Harari, S. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0857-z · Cited by 34
Shi, H., Yin, D., Bonella, F., Kreuter, M., Oltmanns, U., Li, X., Peng, S., & Wei, L. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1121-2 · Cited by 34
“Evidence from the CAPACITY and ASCEND randomized controlled trials (RCTs) showed a significant reduction in the relative decline in forced vital capacity (FVC) over 72 weeks compared to the placebo group [3, 4].”
MethodMechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches
Mohammed, S. M., Al-Saedi, H. F. S., Mohammed, A. Q., Amir, A. A., Radi, U. K., Sattar, R., Ahmad, I., Ramadan, M. F., Alshahrani, M. Y., Balasim, H. M., et al. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01384-9 · Cited by 46
The pathophysiologic basis of abdominal aortic aneurysm progression: a critical appraisal
Lindeman, J. H. N. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1052408 · Cited by 42
Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences
Harari, S. A., & Caminati, A. (2015) · European Respiratory Review · doi:10.1183/16000617.0042-2015 · Cited by 36
Riches, D. W. H., Backos, D. S., & Redente, E. F. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.005 · Cited by 32
Gruden, J. F., Panse, P. M., Gotway, M. B., Jensen, E. A., Wellnitz, C. V., & Wesselius, L. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.15.14525 · Cited by 34
Martin, M. D., Chung, J. H., & Kanne, J. P. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000204 · Cited by 38
Zou, R. H., Nouraie, M. S., Chen, X., Saul, M. I., Kaminski, N., Gibson, K. F., Kass, D. J., & Lindell, K. O. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0400 · Cited by 33
Ullah, A., Wang, K., Wu, P., Oupický, D., & Sun, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s171280 · Cited by 32
Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
Balestro, E., Cocconcelli, E., Tinè, M., Biondini, D., Faccioli, E., Saetta, M. P., & Rea, F. (2019) · Medicina · doi:10.3390/medicina55100702 · Cited by 38
“Despite the availability of effective pharmacologic treatments for IPF [15,16], LTx is so far the only treatment with proven benefit on survival for carefully selected patients with advanced disease and respiratory failure.”
BackgroundClinical course and management of idiopathic pulmonary fibrosis
Quinn, C., Wisse, A., & Manns, S. T. (2019) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-019-0197-0 · Cited by 46
Lee, S., Micalizzi, D. S., Truesdell, S. S., Bukhari, S. I. A., Boukhali, M., Story, J. L., Kato, Y., Choo, M., Dey‐Guha, I., Ji, F., et al. (2020) · Genome biology · doi:10.1186/s13059-020-1936-4 · Cited by 33
He, N., Wang, Y., Huang, Y. L., Wang, X., Chen, L., & Lv, C. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128565 · Cited by 32
Li, X., Liu, X., Deng, R., Gao, S., Jiang, Q., Liu, R., Li, H., Yang, M., Zhai, Y., Zhang, S., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153428 · Cited by 36
Johannson, K. A., Lethebe, B. C., Assayag, D., Fisher, J. H., Kolb, M. R. J., Morisset, J., Shapera, S., Gershon, A. S., Hambly, N., Khalil, N., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-216oc · Cited by 40
Clusters of comorbidities in idiopathic pulmonary fibrosis
Prior, T. S., Hoyer, N., Hilberg, O., Shaker, S. B., Davidsen, J. R., Rasmussen, F., & Bendstrup, E. M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106490 · Cited by 38
Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases
Tomassetti, S., Ravaglia, C., Puglisi, S., Ryu, J. H., Colby, T. V., Cavazza, A., Wells, A. U., Pavone, M., Vancheri, C., Lavorini, F., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202104-466oc · Cited by 35
Lasky, J. A., Case, A., Unterman, A., Kreuter, M., Scholand, M. B., Chaudhary, S., Lofaro, L. R., Johnson, M., Huang, J., Bhorade, S. M., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202107-897oc · Cited by 34
Dong, H., Xue, T., Liu, Y., He, S., Yi, Y., Zhang, B., Xin, J., Wang, Z., & Li, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7038834 · Cited by 33
Branco, H., Oliveira, J., Antunes, C., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073631 · Cited by 33
The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Jiang, A., Liu, N., Wang, J., Zheng, X., Ren, M., Zhang, W., & Yao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022228 · Cited by 34
Liposomal hydrogel formulation for transdermal delivery of pirfenidone
Jose, A., Mandapalli, P. K., & Venuganti, V. V. K. (2015) · Journal of Liposome Research · doi:10.3109/08982104.2015.1060611 · Cited by 33
Near-infrared fluorescent Aza-BODIPY dyes: Rational structural design and biomedical imaging
Zhao, B., Liao, L., Zhu, Y., Hu, Z., & Wu, F. (2023) · Journal of Luminescence · doi:10.1016/j.jlumin.2023.120099 · Cited by 31
Tikellis, G., Hoffman, M., Mellerick, C., Burge, A. T., & Holland, A. E. (2023) · European Respiratory Review · doi:10.1183/16000617.0066-2023 · Cited by 37
HSP47: A Therapeutic Target in Pulmonary Fibrosis
Sakamoto, N., Okuno, D., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Tanaka, Y., & Mukae, H. (2023) · Biomedicines · doi:10.3390/biomedicines11092387 · Cited by 39
“Pirfenidone is a bioavailable, orally administered synthetic molecule, and is beneficial in patients with IPF as it reduces disease progression and lowers mortality [4,76].”
BackgroundCirculating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
Summer, R. S., Todd, J. L., Neely, M. L., Lobo, L. J., Namen, A. M., Newby, L. K., Shafazand, S., Suliman, S. A., Heßlinger, C., Keller, S., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02644-7 · Cited by 35
Pharmacological treatment of idiopathic pulmonary fibrosis: an update
Spagnolo, P., Wells, A. U., & Collard, H. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.001 · Cited by 33
Swigris, J. J., Olson, A. L., & Brown, K. K. (2016) · Patient Related Outcome Measures · doi:10.2147/prom.s74857 · Cited by 37
Self-citationKim, M., Lee, S. M., Song, J., Do, K., Lee, H. J., Lim, S., Choe, J., Park, K. J., Park, H. J., Kim, H. J., et al. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.03.018 · Cited by 33
Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
Moor, C. C., Heukels, P., Kool, M., & Wijsenbeek, M. S. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00226 · Cited by 34
Behr, J., Nathan, S. D., Harari, S. A., Wuyts, W. A., Kirchgaessler, K.-U., Bengus, M., Gilberg, F., & Wells, A. U. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.03.019 · Cited by 32
Self-citationChambers, D. M., Moretti, L., Zhang, J. J., Cooper, S. W., Chambers, D. M., Santangelo, P. J., & Barker, T. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003658 · Cited by 36
“The medical management of fibrotic diseases, such as pulmonary fibrosis, has enjoyed recent success with the approval of pirfenidone, an “anti-fibrotic agent,” and nintedanib, an inhibitor of multiple tyrosine kinase receptors, after years of failed clinical trials with a variety of other agents, including anti-inflam…”
BackgroundLiang, J., Liu, N., Liu, X., Mena, J. M., Xie, T., Geng, Y., Huan, C., Zhang, Y., Taghavifar, F., Huang, G., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0033oc · Cited by 33
Self-citationDuan, F., Barrón, G. M., Meliton, A. Y., Mutlu, G. M., Dulin, N. O., & Schuger, L. A. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0028oc · Cited by 38
Mackintosh, J. A., Munsif, M., Ranzenbacher, L., Thomson, C., Musk, M., Snell, G. I., Glanville, A. R., Chambers, D. C., & Hopkins, P. M.-A. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.02.005 · Cited by 35
Self-citationNie, Y., Yu, K., Li, B., Hu, Y., Zhang, H., Xin, R., Xiong, Y., Zhao, P., & Chai, G. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.03.002 · Cited by 35
Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases
Hong, J., & Yun, C. (2019) · Cells · doi:10.3390/cells8050392 · Cited by 35
“Despite few Food and Drug Administration (FDA)-approved drugs currently available for IPF, these drugs only slow disease progression, but are not curative [40,41].”
BackgroundKasam, R. K., Reddy, G. B., Jegga, A. G., & Madala, S. K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00532 · Cited by 30
Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing
Lorenzo-Salazar, J. M., Ma, S., Jou, J., Hou, P., Guillén‐Guío, B., Allen, R. J., Jenkins, G. R., Wain, L. V., Oldham, J. M., Noth, I., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00071-2019 · Cited by 34
“IPF remains an incurable condition, although lung transplant can improve long-term survival [2] and two antifibrotic therapies are effective at slowing disease progression [3, 4].”
Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.
Saha, A., Vaidya, P. J., Chavhan, V. B., Achlerkar, A., Leuppi, J. D., & Chhajed, P. N. (2018) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v35i1.6393 · Cited by 36
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
Gibson, C. D., Kugler, M. C., Deshwal, H., Munger, J. S., & Condos, R. (2020) · Lung · doi:10.1007/s00408-020-00370-1 · Cited by 32
Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through α2β1 Integrin
Agarwal, M., Goheen, M., Jia, S., Ling, S., White, E. S., & Kim, K. K. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0150oc · Cited by 34
Advanced Pulmonary Sarcoidosis
Gupta, R., & Baughman, R. P. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1709495 · Cited by 37
Dhooria, S., Agarwal, R., Sehgal, I. S., Prasad, K. T., Muth, V., Garg, M. K., Bal, A., Aggarwal, A. N., & Behera, D. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.8718 · Cited by 40
Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
Samarelli, A. V., Tonelli, R., Heijink, I. H., Medina, A. M., Marchioni, A., Bruzzi, G., Castaniere, I., Andrisani, D., Gozzi, F., Manicardi, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692551 · Cited by 36
Ray, T., Ryusaki, T., & Ray, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721959 · Cited by 34
Kumari, J., Wagener, F. A. D. T. G., & Kouwer, P. H. J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02549 · Cited by 32
Lee, C. T., Strek, M. E., Adegunsoye, A., Wong, A. W., Assayag, D., Cox, G., Fell, C. D., Fisher, J. H., Gershon, A. S., Halayko, A. J., et al. (2022) · Respirology · doi:10.1111/resp.14267 · Cited by 33
The kidney matrisome in health, aging, and disease
Lausecker, F., Lennon, R., & Randles, M. J. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.029 · Cited by 30
Li, S., Zhou, X., Zeng, R., Lin, L., Zou, X., Yan, Y., Lu, Z., Xia, J., Zhang, L., Ni, S.-Z., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.323 · Cited by 33
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
“The study demonstrated that there was nearly a 50% reduction in the proportion of patients who had an absolute decline of 10% in the predicted FVC or those that died, the primary endpoints [49].”
BackgroundInfluentialWu, C., Lin, H., & Zhang, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105700 · Cited by 34
Bachmann, J. C., Baumgart, S. J., Uryga, A., Bosteen, M. H., Borghetti, G., Nyberg, M., & Herum, K. M. (2022) · Cells · doi:10.3390/cells11101657 · Cited by 31
Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease
Johnston, J., Dorrian, D., Linden, D. A., Stanel, S. C., Rivera‐Ortega, P., & Chaudhuri, N. (2023) · Cells · doi:10.3390/cells12182238 · Cited by 37
“The current standard of care treatment includes antifibrotic medication to slow down progression medication (Pirfenidone and Nintedanib) [13,14], symptom management, and lung transplant in selected cases.”
BackgroundZheng, B., Marinescu, D.-C., Hague, C. J., Müller, N. L., Murphy, D. T., Churg, A., Wright, J. L., Al-Arnawoot, A., Bilawich, A.-M., Bourgouin, P., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae076 · Cited by 39
Ailanthone ameliorates pulmonary fibrosis by suppressing JUN-dependent MEOX1 activation
Zhao, L., Zhu, Y., Tao, H., Chen, X., Yin, F., Zhang, Y., Qin, J., Huang, Y., Cai, B., Lin, Y., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.013 · Cited by 32
Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era
Podolanczuk, A. J., & Raghu, G. (2024) · European Respiratory Journal · doi:10.1183/13993003.01305-2024 · Cited by 31
PI3K/Akt in IPF: untangling fibrosis and charting therapies
Bhatt, J., Ghigo, A., & Hirsch, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1549277 · Cited by 41
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 59
Cutting edge: FasL+ immune cells promote resolution of fibrosis
Wallach‐Dayan, S. B., Elkayam, L., Golan‐Gerstl, R., Konikov-Rozenman, J., Zisman, P., Richter-Dayan, M., Arish, N., & Breuer, R. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.02.006 · Cited by 34
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 33
Nikolaou, A. I., Ninou, I., Kokotou, M. G., Kaffe, E., Afantitis, A., Aidinis, V., & Kokotos, G. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00232 · Cited by 32
Goto, T. (2018) · Cancers · doi:10.3390/cancers10070223 · Cited by 31
“For the treatment of IPF, the most common subtype of IP, the oral anti-fibrotic agent pirfenidone was demonstrated to improve progression-free survival by suppressing progression of IPF in a recent phase III trial [56].”
SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice
Shou, J., Cao, J., Zhang, S., Sun, R., Zhao, M., Chen, K., Su, S. B., Yang, J., & Yang, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.06.072 · Cited by 31
Holtze, C. H., Flaherty, K. R., Kreuter, M., Luppi, F., Moua, T., Vancheri, C., & Scholand, M. B. (2018) · European Respiratory Review · doi:10.1183/16000617.0078-2018 · Cited by 33
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis
Collison, A., Li, J., de Siqueira, A. P., Lv, X., Toop, H. D., Morris, J. C., Starkey, M. R., Hansbro, P. M., Zhang, J., & Mattes, J. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0786-x · Cited by 33
Ikeda, S., Sekine, A., Baba, T., Katano, T., Tabata, E., Shintani, R., Sadoyama, S., Yamakawa, H., Oda, T., Okuda, R., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0841-7 · Cited by 31
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Valenzuela, C., Torrisi, S. E., Kahn, N. C., Quaresma, M., Stowasser, S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-019-1269-6 · Cited by 32
Mori, Y., Nishikiori, H., Chiba, H., Yamada, G., Kuronuma, K., & Takahashi, H. (2020) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2020.103386 · Cited by 32
Nathan, S. D., Yang, M., Morgenthien, E. A., & Stauffer, J. L. (2020) · European Respiratory Journal · doi:10.1183/13993003.02151-2019 · Cited by 35
Self-citationPirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
Vietri, L., Cameli, P., Perruzza, M., Cekorja, B., Bergantini, L., d’Alessandro, M., Refini, R. M., Pieroni, M., Fossi, A., Bennett, D., et al. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620906326 · Cited by 33
Southern, B. D. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.ccc026 · Cited by 31
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
Makino, S. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1826665 · Cited by 35
New Perspectives on the Aberrant Alveolar Repair of Idiopathic Pulmonary Fibrosis
Wang, Z. N., & Tang, X. X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580026 · Cited by 35
Kato, M., Sasaki, S., Tateyama, M., Arai, Y., Motomura, H., Sumiyoshi, I., Ochi, Y., Watanabe, J. A., Ihara, H., Togo, S., et al. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s284819 · Cited by 36
Li, S., Shao, L., Fang, J., Zhang, J., Chen, Y., Yeo, A. J., Lavin, M. F., Yu, G., & Shao, H. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9728 · Cited by 30
Long non‐coding RNAs: Promising new targets in pulmonary fibrosis
Zhang, S., Chen, H., Yue, D., Blackwell, T. S., Lv, C., & Song, X. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3318 · Cited by 31
Hariri, L. P., Roden, A. C., Chung, J. H., Danoff, S. K., Manjarres, D. C. G., Hartwig, M. G., Kheir, F. M., King, C. S., Kreider, M. E., Lynch, D. A., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202009-1179fr · Cited by 35
Self-citationPost-COVID-19 pulmonary fibrosis: A case series and review of literature
Rai, D. K., Kumar, S., & Sahay, N. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2126_20 · Cited by 31
Khan, F., Howard, L., Hearson, G., Edwards, C., Barber, C., Jones, S., Wilson, A. M., Maher, T. M., Saini, G., Stewart, I., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-612rl · Cited by 31
Jegal, Y., Park, J. S., Kim, S. Y., Yoo, H., Jeong, S. H., Song, J. W., Lee, J. H., Lee, H. L., Choi, S. M., Kim, Y. W., et al. (2021) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2021.0123 · Cited by 38
Wu, W., Qiu, L., Wu, J., Liu, X., & Zhang, G. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050004 · Cited by 35
Raghu, G., Hamblin, M. J., Brown, A., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vašáková, M., Pesci, A., Antin-Ozerkis, D. E., Meyer, K. C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02047-0 · Cited by 33
Spatially distinct molecular patterns of gene expression in idiopathic pulmonary fibrosis
Blumhagen, R. Z., Kurche, J. S., Cool, C. D., Walts, A. D., Heinz, D. E., Fingerlin, T. E., Yang, I. V., & Schwartz, D. A. (2023) · Respiratory Research · doi:10.1186/s12931-023-02572-6 · Cited by 34
A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep
Organ, L. A., Bacci, B., Koumoundouros, E., Barcham, G., Kimpton, W. G., Nowell, C. J., Samuel, C. S., & Snibson, K. J. (2014) · Experimental Lung Research · doi:10.3109/01902148.2014.985806 · Cited by 30
Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats
Zhou, X., CAO, Z.-D., Xiao, N., Shen, Q., & Li, J. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2435 · Cited by 30
Hasdemir, P. S., Özkut, M. M., Güvenal, T., Üner, M. A., Çalık, E., Koltan, S. O., Koyuncu, F. M., & Özbilgin, K. (2016) · Journal of Investigative Surgery · doi:10.1080/08941939.2016.1215578 · Cited by 31
Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis
Spagnolo, P., & Wuyts, W. A. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000405 · Cited by 36
Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
Sathiyamoorthy, G., Sehgal, S., & Ashton, R. W. (2017) · Southern Medical Journal · doi:10.14423/smj.0000000000000655 · Cited by 30
Li, F., Han, F., Li, H., Zhang, J., Qiao, X., Shi, J., Li, Y., Dong, J., Luo, M., Wei, J., et al. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.06.032 · Cited by 30
Systematic review of drug effects in humans and models with surfactant-processing disease
Klay, D., Hoffman, T. W., Harmsze, A. M., Grutters, J. C., & van Moorsel, C. H. M. (2018) · European Respiratory Review · doi:10.1183/16000617.0135-2017 · Cited by 32
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.